PDCD1 and breast carcinoma: designed antisense oligonucleotides to efficiently knock down CD39 in regulatory T cells and TAMs in a mice model of breast cancer, thereby improving the response to anti-PD-1 antibody by upregulating PD-1 expression on CD8+ T cells (181).